EUVIMEDEUVIMED entdecken
Crossref

Precision adjuvant therapy after nephrectomy for high-risk clear-cell renal cell carcinoma: a narrative review

Patricia Rodríguez Parras, Alberto Zambudio Munuera, Irene Millán Ramos, Ana Morales Martínez, Francisco Gutiérrez Tejero, Miguel Ángel Arrabal Polo

Uro-Technology Journal · 25.09.2026 · 10 (3)

DOI: 10.31491/utj.2026.09.066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Uro-Technology Journal, online erschienen am 30.09.2026. Verfasst von Patricia Rodríguez Parras und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant therapy for renal cell carcinoma has moved from repeated negative trials to an evolving postopera-tive treatment landscape. Pembrolizumab is the first systemic therapy after nephrectomy to demonstrate both disease-free survival (DFS) and overall survival (OS) benefit in patients with clear-cell renal cell carcinoma (ccRCC) at increased risk of recurrence. However, clinicopathological eligibility exposes some patients already cured by surgery to immune-related toxicity and cannot identify microscopic residual disease. This narrative review integrates mature KEYNOTE-564 outcomes, the active-control LITESPARK-022 trial of pembrolizumab plus belzutifan, RAMPART findings, prior negative immune-checkpoint inhibitor and tyrosine-kinase inhibi-tor trials, and emerging biomarkers. We explicitly distinguish established standard care, promising but not yet mature strategies, and interventions that remain investigational. One year of pembrolizumab is the estab-lished evidence-based option for medically suitable KEYNOTE-564-eligible patients. Pembrolizumab plus bel-zutifan improves DFS versus pembrolizumab alone and is approved in the United States, but OS is immature, toxicity is greater, and its place in other regions remains unsettled. Dual-checkpoint blockade, postoperative treatment allocation based on kidney injury molecule-1 (KIM-1) or circulating tumor DNA (ctDNA), molecular subtypes, programmed death-ligand 1 expression, and radiomics remain investigational. No biomarker is vali-dated to select routine adjuvant therapy, and efficacy in non-clear-cell histologies has not been established. We propose a conceptual three-axis framework integrating clinicopathological recurrence risk, candidate residu-al-disease signals, and treatment fitness or patient preference. It is a decision aid, not a validated algorithm. At present, precision resides mainly in risk stratification, fitness assessment, and shared decision-making; mo-lecular treatment selection awaits prospective validation. Keywords : Renal cell carcinoma, precision oncology, targeted therapy, immunotherapy, biomarkers

Zitieren

APA

Parras, P. R., Munuera, A. Z., Ramos, I. M., Martínez, A. M., Tejero, F. G., & Polo, M. Á. A. (2026). Precision adjuvant therapy after nephrectomy for high-risk clear-cell renal cell carcinoma: a narrative review. Uro-Technology Journal, 10(3). https://doi.org/10.31491/utj.2026.09.066

Vancouver

Parras PR, Munuera AZ, Ramos IM, Martínez AM, Tejero FG, Polo MÁA. Precision adjuvant therapy after nephrectomy for high-risk clear-cell renal cell carcinoma: a narrative review. Uro-Technology Journal. 2026;10(3). doi:10.31491/utj.2026.09.066

BibTeX
@article{Parras2026,
  author = {Parras, Patricia Rodríguez and Munuera, Alberto Zambudio and Ramos, Irene Millán and Martínez, Ana Morales and Tejero, Francisco Gutiérrez and Polo, Miguel Ángel Arrabal},
  title = {Precision adjuvant therapy after nephrectomy for high-risk clear-cell renal cell carcinoma: a narrative review},
  journal = {Uro-Technology Journal},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.31491/utj.2026.09.066}
}
Kostenlos starten →